ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
43 hedge funds and large institutions have $77.9M invested in Adaptimmune Therapeutics in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Holders
43
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$625K | |
| 2 | +$381K | |
| 3 | +$160K | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$131K |
| 5 |
HF
HRT Financial
New York
|
+$47.2K |
Top Sellers
| 1 | -$1.61M | |
| 2 | -$1.25M | |
| 3 | -$1.03M | |
| 4 |
Millennium Management
New York
|
-$449K |
| 5 |
Morgan Stanley
New York
|
-$403K |